The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tumor-educated Platelets in Venous Thromboembolism
Official Title: Platelet RNA Profiling to Detect Occult Cancer in Patients With Unprovoked Venous Thromboembolism
Study ID: NCT02739867
Brief Summary: Among patients with a first episode of unprovoked venous thromboembolism (VTE), the contemporary one-year risk of detecting occult cancer is approximately 4% to 7%. Of these cases, 30% to 60% are missed by routine limited screening for cancer. RNA profiling of platelets is a promising, highly accurate biomarker for cancer detection, but its clinical utility in patients with unprovoked VTE is unknown. The objective of the present study is to evaluate the diagnostic accuracy of platelet RNA profiling in detecting occult cancer in patients with unprovoked venous thromboembolism. Secondary objectives include evaluation of other biomarkers for cancer, prediction of bleeding, and prediction of recurrent VTE.
Detailed Description:
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
KU Leuven, Leuven, , Belgium
Ottawa Hospital, Ottawa, , Canada
Dresden University Clinic, Dresden, , Germany
Bologna University Hospital, Bologna, , Italy
Gabriele D'Annunzio University, Chieti, , Italy
University of Padua, Padua, , Italy
University of Insubria, Varese, , Italy
Academic Medical Center, Amsterdam, Noord-Holland, Netherlands
Flevoziekenhuis, Almere, , Netherlands
Slotervaartziekenhuis, Amsterdam, , Netherlands
VU medical center, Amsterdam, , Netherlands
Tergooiziekenhuizen, Hilversum, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Hospital Universitario Virgen del Rocio, Sevilla, , Spain
Name: Harry Büller, MD, PhD
Affiliation: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Role: STUDY_CHAIR